Generation of genetically-modified human differentiated cells for toxicological tests and the study of neurodegenerative diseases
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Human differentiated cell types, such as neurons or hepatocytes, are of limited availability, and their use for experiments requiring ectopic gene expression is challenging. Using the human conditionally-immortalized neuronal precursor line LUHMES, we explored whether genetic modification in the proliferating state could be used for experiments in the differentiated post-mitotic neurons. First, alpha-synuclein (ASYN), a gene associated with the pathology of Parkinson's disease, was overexpressed. Increased amounts of the protein were tolerated without change of phenotype, and this approach now allows further studies on protein variants. Knockdown of ASYN attenuated the toxicity of the parkinsonian toxicant 1-methyl-4-phenylpyridinium (MPP+). Different lentiviral constructs then were tested: cells labeled ubiquitously with green (GFP) or red fluorescent protein (RFP) allowed the quantification of neurite growth and of its disturbance by toxicants; expression of proteins of interest could be targeted to different organelles; production of two different proteins from a single read-through construct was achieved successfully by an expression strategy using a linker peptide between the two proteins, which is cleaved by deubiquitinases; LUHMES, labeled with GFP in the cytosol and RFP in the mitochondria, were used to quantify mitochondrial mobility along the neurites. MPP+ reduced such organelle movement before any other detectable cellular change, and this toxicity was prevented by simultaneous treatment with the antioxidant ascorbic acid. Thus, a strategy has been outlined here to study new functional endpoints, and subtle changes of structure and proteostasis relevant in toxicology and biomedicine in post-mitotic human cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As examples, constitutive CMV-based promoters drastically change activity during differentiation of LUHMES cells (Scholz et al., 2018; Schildknecht et al., 2013)”
From Guidance document on Good cell and tissue culture practice 2.0 (GCCP 2.0) (2021) · cites this paper as Schildknecht et al., 2013
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
-Synuclein in Parkinson's Disease
Stefanis, L. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009399 · Cited by 1,446 · cited 1×
“Although a defined physiological function of ASYN has so far only poorly been described, evidence is accumulating that it is involved in modulating synaptic transmission (Stefanis, 2012).”
BackgroundAbsence of Wallerian Degeneration does not Hinder Regeneration in Peripheral Nerve
Lunn, E. R., Perry, V. H., Brown, M. C., Rosen, H., & Gordon, S. (1989) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.1989.tb00771.x · Cited by 646 · cited 1×
“For example, we have chosen the protein wld(s) (Wallerian degeneration, slow) that was originally identified in mice displaying delayed Wallerian degeneration (Lunn et al., 1989).”
MethodWallerian degeneration of injured axons and synapses is delayed by a Ube4b/Nmnat chimeric gene
Mack, T. G. A., Reiner, M., Beirowski, B., Mi, W., Emanuelli, M., Wagner, D., Thomson, D., Gillingwater, T., Court, F., Conforti, L., et al. (2001) · Nature Neuroscience · doi:10.1038/nn770 · Cited by 611
Neuronal regulation of astroglial morphology and proliferation in vitro.
Hatten, M. E. (1985) · The Journal of cell biology · doi:10.1083/jcb.100.2.384 · Cited by 592
Schildknecht, S., Gerding, H. R., Karreman, C., Drescher, M., Lashuel, H. A., Outeiro, T. F., Di Monte, D. A., & Leist, M. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12226 · Cited by 148 · cited 1×
“High levels of ASYN may serve as a reversible “antioxidant” (Schildknecht et al., 2013).”
BackgroundSelf-citationRathke‐Hartlieb, S., Kahle, P. J., Neumann, M., Ozmen, L., Haid, S., Okochi, M., Haass, C., & Schulz, J. B. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00366.x · Cited by 128
Uncoupling of ATP-depletion and cell death in human dopaminergic neurons
Pöltl, D., Schildknecht, S., Karreman, C., & Leist, M. (2012) · NeuroToxicology · doi:10.1016/j.neuro.2011.12.007 · Cited by 49
Self-citation
Cited by
Do Van, B., Gouel, F., Jonneaux, A., Timmerman, K., Gelé, P., Pétrault, M., Bastide, M., Laloux, C., Moreau, C., Bordet, R., et al. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.05.011 · Cited by 689
“The robust neuronal status of LUHMES cells has been extensively studied (Schildknecht et al., 2013).”
Adverse outcome pathways: opportunities, limitations and open questions
Leist, M., Ghallab, A., Graepel, R., Marchan, R., Hassan, R., Bennekou, S. H., Limonciel, A., Vinken, M., Schildknecht, S., Waldmann, T., et al. (2017) · Archives of Toxicology · doi:10.1007/s00204-017-2045-3 · Cited by 394
Self-citationGuidance document on Good cell and tissue culture practice 2.0 (GCCP 2.0)
Pamies, D. (2021) · ALTEX · doi:10.14573/altex.2111011 · Cited by 100
Leite, P. E. C., Pereira, M. R., Harris, G., Pamies, D., dos Santos, L. M. G., Granjeiro, J. M., Hogberg, H. T., Hartung, T., & Smirnova, L. (2019) · Particle and Fibre Toxicology · doi:10.1186/s12989-019-0307-3 · Cited by 92
https://www.altex.org/index.php/altex/article/view/1339
Krebs, A., Waldmann, T., Wilks, M. F., van Vugt-Lussenburg, B. M. A., van der Burg, B., Terron, A., Steger-Hartmann, T., Ruegg, J., Rovida, C., Pedersen, E., et al. (2019) · ALTEX · doi:10.14573/altex.1909271 · Cited by 77
Metadata
- Authors
- Schildknecht, S.
- Venue
- ALTEX
- Publisher
- ALTEX Edition
- Published
- 2013
- Volume
- 30
- Issue
- 4
- Pages
- 427-444
- ISSN
- 0946-7785 (ISSN-L)
- 1868-596X
- OpenAlex
- W2025494835
- Cited by
- 85
- References
- 7
- FWCI
- 4.18
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.